Recently, several phase I and II clinical trials (NCT05242965, NCT05455658, NCT02157051) have commenced for STEMVAC, a DNA plasmid-based vaccine that targets multiple cancer antigens, including SOX2. This evidence concerns the gene SOX2 and cancer.